XML 56 R44.htm IDEA: XBRL DOCUMENT

Commitments

12 Months Ended

Jun. 30, 2025

Note 34. Commitments

(i)

Contracted and committed Research projects and license commitments

The Group has entered into research and development contracts and intellectual property license agreements with various third parties in respect of services for the Phase 3 wet AMD clinical trial and the clinical grade manufacture of sozinibercept. Expenditure commitments relating to these, and intellectual property license agreements are payable as follows:


	2025		2024		2023
	US$(000's)		US$(000's)		US$(000's)
Within one year		85		27,383		12,633
After one year but not more than five years		60		3,504		12,302
After more than five years		—		15		30
		145		30,902		24,965

Currently, the biggest research contract has a 60 day termination clause and all commitments have been limited to a twelve month commitment.

(ii)

Commercial commitments

The Group has entered into commercial agreements with various third parties in respect of services for preparation of OPT‑302 for launch and pre‑marketing phase. Expenditure commitments relating to these activities are payable as follows:


	2025		2024		2023
	US$(000's)		US$(000's)		US$(000's)
Within one year		—		63		47
After one year but not more than five years		—		—		—
After more than five years		—		—		—
		—		63		47